Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rein Therapeutics (RNTX) Accumulated Expenses (2016 - 2025)

Rein Therapeutics filings provide 10 years of Accumulated Expenses readings, the most recent being $2.2 million for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses rose 49.53% year-over-year to $2.2 million, compared with a TTM value of $2.2 million through Dec 2025, up 49.53%, and an annual FY2025 reading of $2.2 million, up 49.53% over the prior year.
  • Accumulated Expenses hit $2.2 million in Q4 2025 for Rein Therapeutics, up from $1.6 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $3.2 million in Q2 2021, with the low at $145000.0 in Q1 2023.
  • Median Accumulated Expenses over the past 5 years was $1.2 million (2021), compared with a mean of $1.2 million.
  • The sharpest move saw Accumulated Expenses tumbled 77.81% in 2022, then soared 189.66% in 2024.
  • Year by year, Accumulated Expenses stood at $1.2 million in 2021, then tumbled by 64.04% to $425000.0 in 2022, then skyrocketed by 177.18% to $1.2 million in 2023, then grew by 25.13% to $1.5 million in 2024, then soared by 49.53% to $2.2 million in 2025.
  • According to Business Quant data, Accumulated Expenses over the past three periods came in at $2.2 million, $1.6 million, and $1.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.